论文部分内容阅读
近来,循环肿瘤细胞(circulating tumor cells,CTCs)作为潜在的预后标志物和预测转移进展的可靠手段在肿瘤研究中引起了密切关注。早在19世纪就有多名科学家和医生对CTCs进行了描述,其存在作为发生远端转移的必要条件并非新的概念。然而直到最近,能够准确识别癌症患者血液中CTCs的生物技术才得到广泛运用。例如,基于免疫磁性技术的CellSearch(Veridex,LLC),由包覆抗上皮细胞黏附分子(epithelial cell adhesion molecule,EpCAM)抗体的磁性纳米颗粒组成,是目前CTCs的最佳检测系
Recently, circulating tumor cells (CTCs) have attracted close attention in tumor research as a potential prognostic marker and a reliable means to predict metastasis progression. As early as the 19th century, many scientists and doctors described CTCs, and their existence as a necessary condition for distant metastasis is not a new concept. However, until recently, biotechnology that can accurately identify CTCs in the blood of cancer patients has been widely used. For example, CellSearch (Veridex, LLC) based on immunomagnetic technology consists of magnetic nanoparticles coated with antibodies against epithelial cell adhesion molecule (EpCAM) and is currently the best detection system for CTCs.